Sandu Pharma.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE751D01014
NSEID:
BSEID: 524703
View on BSE

INR

41.59

0.24 (0.58%)

BSENSE

Jul 03, 03:30 PM

BSE+NSE Vol: 2.91 k

{
  "main_header": {
    "sid": 764862,
    "name": "Sandu Pharma.",
    "stock_name": "Sandu Pharma.",
    "full_name": "Sandu Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/sandu-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "41.59",
    "chg": 0.24,
    "chgp": "0.58%",
    "dir": 1,
    "prev_price": "41.35",
    "mcapval": "40.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524703,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 49,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE751D01014",
    "curr_date": "Jul 03, 03:30 PM",
    "curr_time": "08:26 AM",
    "last_traded_at": "Jul 03, 03:30 PM IST",
    "bse_nse_vol": "2.91 k",
    "exc_status": "Active",
    "traded_date": "Jul 03, 2026",
    "traded_date_str": "2026 07 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sandu-pharma-764862-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Sandu Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sandu-pharmaceuticals-ltd-is-rated-sell-4081607",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/SanduPharmaceut_mojoScore_4081607.png",
        "date": "2026-07-01 10:10:03",
        "description": "Sandu Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Sandu Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sandu-pharmaceuticals-ltd-is-rated-sell-4061151",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/SanduPharmaceut_mojoScore_4061151.png",
        "date": "2026-06-18 10:10:04",
        "description": "Sandu Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 18 June 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Golden Cross Forms in Sandu Pharmaceuticals Ltd Amid Mixed Technical Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-ltd-forms-golden-cross-signalling-potential-bullish-breakout-4054643",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/SanduPharmaceut_goldencross_4054643.png",
        "date": "2026-06-15 18:00:45",
        "description": "The 50-day moving average has crossed above the 200-day moving average for Sandu Pharmaceuticals Ltd, signalling a golden cross on 15 Jun 2026. Yet, the stock’s recent price action and a mixed technical backdrop suggest this signal warrants a cautious interpretation rather than an outright bullish endorsement."
      },
      {
        "title": "Sandu Pharmaceuticals Ltd Upgraded to Sell on Technical and Valuation Improvements",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sandu-pharmaceuticals-ltd-upgraded-to-sell-on-technical-and-valuation-improvements-4030077",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/SanduPharmaceut_mojoScore_4030077.png",
        "date": "2026-06-02 08:27:52",
        "description": "Sandu Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 1 June 2026, reflecting notable improvements in its technical outlook and valuation metrics despite ongoing fundamental challenges. The micro-cap pharmaceutical company’s Mojo Score rose to 37.0, signalling a cautious but more optimistic stance among analysts."
      },
      {
        "title": "Sandu Pharmaceuticals Gains 7.69%: 2 Key Factors Driving the Week’s Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-gains-769-2-key-factors-driving-the-weeks-volatility-4023153",
        "imagepath": "",
        "date": "2026-05-30 15:05:00",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>25 May:</strong> Stock opens at Rs.39.96, gaining 2.46%</p>\n                    <p><strong>26 May:</strong> Sharp rally of 10.46% to Rs.44.14 despite downgrade</p>\n                    <p><strong>27 May:</strong> Downgrade to Strong Sell announced; price steady at Rs.44.13</p>\n                    <p><strong>29 May:</strong> Week closes at Rs.42.00, down 4.83% on the day</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.39.00</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.42.00</div><..."
      },
      {
        "title": "Sandu Pharmaceuticals Downgraded to Strong Sell Amid Mixed Valuation and Weak Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sandu-pharmaceuticals-downgraded-to-strong-sell-amid-mixed-valuation-and-weak-fundamentals-4015911",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SanduPharmaceut_mojoScore_4015911.png",
        "date": "2026-05-27 08:07:38",
        "description": "Sandu Pharmaceuticals Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 26 May 2026, reflecting a complex interplay of valuation improvements offset by deteriorating financial trends and weak quality metrics. Despite an attractive valuation profile, the company’s long-term fundamentals and technical outlook remain concerning, prompting a cautious stance from analysts."
      },
      {
        "title": "Sandu Pharmaceuticals Ltd Valuation Shifts Signal Changing Market Sentiment",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-ltd-valuation-shifts-signal-changing-market-sentiment-4015589",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SanduPharmaceut_valuationdot_4015589.png",
        "date": "2026-05-27 08:01:05",
        "description": "Sandu Pharmaceuticals Ltd has seen a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, despite a challenging market backdrop and a recent upgrade to a Strong Sell Mojo Grade. This article analyses the company’s current price-to-earnings (P/E) and price-to-book value (P/BV) ratios in comparison to historical averages and peer benchmarks, providing a comprehensive view of its price attractiveness and investment potential."
      },
      {
        "title": "Sandu Pharmaceuticals Declines 2.37% Despite Valuation Upgrade: 2 Key Factors Driving the Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-declines-237-despite-valuation-upgrade-2-key-factors-driving-the-week-3994562",
        "imagepath": "",
        "date": "2026-05-16 15:08:59",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>11 May:</strong> Stock opens at Rs.39.02, down 0.76% as Sensex falls 1.40%</p>\n                    <p><strong>12 May:</strong> Continued decline to Rs.38.46 amid broader market weakness</p>\n                    <p><strong>13 May:</strong> Stock hits weekly low of Rs.37.48 following valuation upgrade announcement</p>\n                    <p><strong>14 May:</strong> MarketsMOJO upgrades rating to Sell on improved valuation metrics</p>\n                    <p><strong>15 May:</strong> Stock rebounds to Rs.38.39 despite Sensex retreat</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div c..."
      },
      {
        "title": "Sandu Pharmaceuticals Ltd Upgraded to Sell on Improved Valuation Metrics",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sandu-pharmaceuticals-ltd-upgraded-to-sell-on-improved-valuation-metrics-3990572",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SanduPharmaceut_mojoScore_3990572.png",
        "date": "2026-05-14 08:10:05",
        "description": "Sandu Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a marked improvement in its valuation metrics despite ongoing challenges in financial performance and technical indicators. This nuanced shift reflects a more attractive entry point for investors, even as the company continues to face headwinds in growth and profitability."
      }
    ],
    "total": 107,
    "sid": "764862",
    "stock_news_url": "https://www.marketsmojo.com/news/sandu-pharmaceuticals-764862"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "24-Jun-2026",
      "details": "intimation about closure of trading window for q ended 30th June 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Demise",
      "datetime": "19-Jun-2026",
      "details": "Intimation about sad demise of our Managing Director Shri Umesh Sandu(DIN:01132141)",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Cessation",
      "datetime": "19-Jun-2026",
      "details": "sad demise of Shri Umesh Sandu as Managing Director(DIN:01132141)",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Sandu Pharmaceuticals Ltd has declared <strong>8%</strong> dividend, ex-date: 18 Sep 25",
          "dt": "2025-09-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Sandu Pharmaceuticals Ltd is Rated Sell

2026-07-01 10:10:03

Sandu Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Sandu Pharmaceuticals Ltd is Rated Sell

2026-06-18 10:10:04

Sandu Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 18 June 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Golden Cross Forms in Sandu Pharmaceuticals Ltd Amid Mixed Technical Signals

2026-06-15 18:00:45

The 50-day moving average has crossed above the 200-day moving average for Sandu Pharmaceuticals Ltd, signalling a golden cross on 15 Jun 2026. Yet, the stock’s recent price action and a mixed technical backdrop suggest this signal warrants a cautious interpretation rather than an outright bullish endorsement.

Read full news article

Sandu Pharmaceuticals Ltd Upgraded to Sell on Technical and Valuation Improvements

2026-06-02 08:27:52

Sandu Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 1 June 2026, reflecting notable improvements in its technical outlook and valuation metrics despite ongoing fundamental challenges. The micro-cap pharmaceutical company’s Mojo Score rose to 37.0, signalling a cautious but more optimistic stance among analysts.

Read full news article

Sandu Pharmaceuticals Gains 7.69%: 2 Key Factors Driving the Week’s Volatility

2026-05-30 15:05:00

Key Events This Week

25 May: Stock opens at Rs.39.96, gaining 2.46%

26 May: Sharp rally of 10.46% to Rs.44.14 despite downgrade

27 May: Downgrade to Strong Sell announced; price steady at Rs.44.13

29 May: Week closes at Rs.42.00, down 4.83% on the day

Read full news article

Sandu Pharmaceuticals Downgraded to Strong Sell Amid Mixed Valuation and Weak Fundamentals

2026-05-27 08:07:38

Sandu Pharmaceuticals Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 26 May 2026, reflecting a complex interplay of valuation improvements offset by deteriorating financial trends and weak quality metrics. Despite an attractive valuation profile, the company’s long-term fundamentals and technical outlook remain concerning, prompting a cautious stance from analysts.

Read full news article

Sandu Pharmaceuticals Ltd Valuation Shifts Signal Changing Market Sentiment

2026-05-27 08:01:05

Sandu Pharmaceuticals Ltd has seen a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, despite a challenging market backdrop and a recent upgrade to a Strong Sell Mojo Grade. This article analyses the company’s current price-to-earnings (P/E) and price-to-book value (P/BV) ratios in comparison to historical averages and peer benchmarks, providing a comprehensive view of its price attractiveness and investment potential.

Read full news article

Sandu Pharmaceuticals Declines 2.37% Despite Valuation Upgrade: 2 Key Factors Driving the Week

2026-05-16 15:08:59

Key Events This Week

11 May: Stock opens at Rs.39.02, down 0.76% as Sensex falls 1.40%

12 May: Continued decline to Rs.38.46 amid broader market weakness

13 May: Stock hits weekly low of Rs.37.48 following valuation upgrade announcement

14 May: MarketsMOJO upgrades rating to Sell on improved valuation metrics

15 May: Stock rebounds to Rs.38.39 despite Sensex retreat

Week Open

Read full news article

Sandu Pharmaceuticals Ltd Upgraded to Sell on Improved Valuation Metrics

2026-05-14 08:10:05

Sandu Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a marked improvement in its valuation metrics despite ongoing challenges in financial performance and technical indicators. This nuanced shift reflects a more attractive entry point for investors, even as the company continues to face headwinds in growth and profitability.